Mazdutide

10mg Vial

2 September 2026Updated 2 September 2026

Mazdutide

Overview Research0 Mechanism Protocols Safety

Discussions

This is Premium content Premium

Create a free account, then upgrade to Premium or Lifetime to unlock the full research article, mechanism of action, results timeline, dosing protocol, and dose calculator for Mazdutide.

Create free account Member login

Full range of benefits for Mazdutide

May reduce appetite and overall caloric intake

Can promote weight loss through appetite suppression

Improves glycaemic control by lowering fasting and postprandial glucose

Associated with reductions in HbA1c in type 2 diabetes

Slows gastric emptying, reducing postprandial glucose spikes

Enhances glucose-dependent insulin secretion

May improve insulin sensitivity and reduce beta‑cell workload

Can modestly lower systolic blood pressure

May improve lipid and inflammatory cardiometabolic markers

Supports reduced cravings and improved eating behaviours

This peptide's combination-safety and interaction data below always stays visible, regardless of membership.

Warning

Important information. The data compiled from scientific literature is provided for educational purposes. Dosage ranges reflect what is reported in studies and do not constitute a recommendation, prescription, or usage guidance. Health decisions should always be made with a qualified professional.

Peptide Interactions

// 16 known interactions

Synergistic(2)Compatible(4)Monitor(5)Avoid(5)

Generally well-tolerated alongside this peptide

Statins

No direct pharmacokinetic interaction is expected and statins can be co-administered with mazdutide for cardiovascular risk reduction without dose adjustment.

ACE inhibitors / ARBs

Antihypertensive therapy with ACE inhibitors or ARBs is pharmacodynamically compatible with mazdutide and generally requires no special co-administration measures.

Proton pump inhibitors (e.g., omeprazole)

PPIs are not expected to have clinically relevant interactions with mazdutide and may be used to manage GI symptoms without routine adjustment.

Aspirin / antiplatelet agents

Low-dose aspirin or standard antiplatelet therapy has a neutral co-administration profile with mazdutide and typically needs no specific modification.

All interaction categories

Synergistic (2)

Metformin: Complementary glucose-lowering mechanisms and weight-moderating effects make metformin a common synergistic partner with mazdutide for improved glycaemic control and weight loss.
SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin): SGLT2 inhibitors provide additive glycaemic lowering, weight reduction and cardiorenal benefits when combined with mazdutide, producing complementary metabolic effects.

Compatible (4)

Statins: No direct pharmacokinetic interaction is expected and statins can be co-administered with mazdutide for cardiovascular risk reduction without dose adjustment.
ACE inhibitors / ARBs: Antihypertensive therapy with ACE inhibitors or ARBs is pharmacodynamically compatible with mazdutide and generally requires no special co-administration measures.
Proton pump inhibitors (e.g., omeprazole): PPIs are not expected to have clinically relevant interactions with mazdutide and may be used to manage GI symptoms without routine adjustment.
Aspirin / antiplatelet agents: Low-dose aspirin or standard antiplatelet therapy has a neutral co-administration profile with mazdutide and typically needs no specific modification.

Monitor (5)

Insulin (basal and bolus): Mazdutide can reduce insulin requirements and increase hypoglycaemia risk, so blood glucose should be closely monitored and insulin doses adjusted as needed.
Sulfonylureas (e.g., glimepiride, gliclazide): Concomitant use increases hypoglycaemia risk and warrants glucose monitoring and consideration of dose reduction of the sulfonylurea.
Warfarin (vitamin K antagonists): Changes in weight, oral intake and potential effects on absorption may alter INR control during mazdutide therapy, so frequent INR monitoring is advised after initiation or dose changes.
Oral drugs with narrow therapeutic indices affected by absorption (e.g., levothyroxine, phenytoin, digoxin): Mazdutide slows gastric emptying which can alter absorption of certain narrow-index oral drugs, so therapeutic levels or clinical effect should be monitored and dosing adjusted if necessary.
Renally active or nephrotoxic agents (e.g., NSAIDs, diuretics): Because GI adverse effects from mazdutide (nausea/vomiting) can cause volume depletion and impact renal function, renal status should be monitored when used with nephrotoxic or renally active drugs.

Avoid (5)

DPP-4 inhibitors (e.g., sitagliptin): Combining DPP-4 inhibitors with mazdutide offers limited incremental glycaemic benefit and represents therapeutic redundancy that should be carefully evaluated.
Other GLP-1 receptor agonists (e.g., liraglutide, semaglutide): Concomitant use duplicates mechanism of action and increases the risk of class adverse effects, so combining mazdutide with another GLP-1 RA is generally inappropriate.
Combined oral contraceptives (estrogen–progestin): Delayed gastric emptying from mazdutide may reduce absorption of oral contraceptives in some patients, so alternative or supplementary contraceptive counselling is prudent.
Drugs associated with pancreatitis (e.g., azathioprine, valproate): Given the class association of GLP-1 receptor agonists with rare pancreatitis, concomitant use of agents that increase pancreatitis risk should prompt careful risk–benefit assessment and monitoring.
Beta-blockers: Beta-blockers can blunt adrenergic symptoms of hypoglycaemia and therefore require cautious use and reinforced glucose monitoring when mazdutide is combined with insulin or insulin secretagogues.